Bile Reflux Scintigraphy After Mini-Gastric Bypass by Saarinen, Tuure et al.
ORIGINAL CONTRIBUTIONS
Bile Reflux Scintigraphy After Mini-Gastric Bypass
Tuure Saarinen1,2 & Jari Räsänen3 & Jarmo Salo3 & Antti Loimaala4 & Miia Pitkonen4 &
Marja Leivonen5 & Anne Juuti1
Published online: 18 February 2017
# Springer Science+Business Media New York 2017
Abstract
Background Significant weight-loss and diabetes remission
have been reported after mini-gastric bypass (MGB).
Concern has been raised regarding postoperative bile reflux
(BR), but it has not been demonstrated in previous studies. We
set out to find out if BR is evident in hepatobiliary scintigra-
phy after MGB.
Methods Nine consecutive patients, seven with type 2 diabe-
tes, underwent MGB (15 cm gastric tube, 250–275 cm biliary
limb) at our institution with a 12-month follow-up, with none
lost to follow-up. Then, 10.7 months (8.6–13.0) after MGB,
all patients underwent hepatobiliary scintigraphy and a reflux
symptom questionnaire (GerdQ) was filled out. A gastroscopy
with biopsies was done for all patients with a bile-reflux-
positive scintigraphy.
Results Mean age at operation was 56 years (41–65) and pre-
operative BMI 43.1 kg/m2 (34.2–54.6). Mean %EWL was
83.9 (49.5–128.3) at 12 months. Four patients reached diabe-
tes remission and two became insulin-independent.
Hepatobiliary scintigraphy showed a transient BR into the
gastric tube for five patients. Bile tracer was found in the
gastric tube at 23–58 min after the tracer injection and highest
activity was 8% (1–8%) at 58 min. Bile tracer was not found
in the esophagus of any of the patients. One patient with a
positive scintigraphy in the gastric tube required re-operation.
Two patients with reflux symptoms had a negative
scintigraphy.
Conclusion Our results indicate that transient bile reflux is
common after MGB in the gastric tube, but not in the esoph-
agus. The clinical relevance of bile reflux needs further
studies.
Keywords Mini-gastric bypass . Single-anastomosis gastric
bypass . Bariatric surgery . Bile reflux . Scintigraphy
Introduction
Laparoscopic mini-gastric bypass (MGB) was developed
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MGB has become increasingly popular among bariatric sur-
geons and is nowadays performed all over the world. Since the
first report by Rutledge et al. in 2001, many reports have
shown good results with MGB regarding weight-loss and ef-
fect on associated diseases, especially type 2 diabetes [1–4]. It
has also been stated that MGB is faster and less prone to
surgical complications compared to the traditional Roux-en-
Y gastric bypass (RYGB) [3, 4]. However, concern has been
raised regarding complications related to MGB procedure, in
particular reflux of jejunal contents including bile and pancre-
atic juices into the gastric tube or even esophagus, in the lit-
erature also referred to as bile reflux (BR) or duodenogastric
reflux [5, 6]. Studies on hepatobiliary scintigraphies, imped-
ance, or intragastric bile measurements after MGB have pre-
viously not been published, that could reveal the presence of
bile in the gastric tube or esophagus. Hepatobiliary scintigra-
phy is a non-invasive and physiologic method for the detec-
tion of bile reflux [7, 8]. It has been shown to be more sensi-
tive and specific compared to gastric juice examinations in the
detection of BR [9].
We started performingMGB in December 2014 in Helsinki
University Hospital. We set out to investigate, whether we can
demonstrate BR after MGB by using dynamic SPECT-




Nine out of 13 patients, who underwent MGB at our institu-
tion between December 2014 and April 2015, were willing to
participate in this study. Bariatric surgery was indicated ac-
cording to international guidelines [10]. Prior to surgery,
Helicobacter pylori was tested and eradicated. All patients
were prescribed multivitamin and calcium supplements after
the operation. All patients had follow-up visits with extensive
blood work including glycohemoglobin (HbA1C), calcium,
iron, and albumin at 1, 3, 6, and 12 months after the surgery.
In addition to standard visits, all patients were invited for a
hepatobiliary scintigraphy 8 to 13 months after the surgery
when patients had been able to lose most of their excess
weight. Prior to the scintigraphy, all patients filled out a
GerdQ questionnaire, which is validated for detection of re-
flux symptoms [11]. All patients, who had signs of BR in
scintigraphy, were also invited for an additional gastroscopy
with biopsies. Surgical ethical committee of Helsinki
University Hospital approved the study design and informed
consent was obtained from all individual participants included
in the study. Weight-loss is reported as excess weight-loss
(%EWL), calculated from the weight at preoperative visit.
Numeric values are reported as mean (min–max).
Surgical Technique
Our technique is essentially similar to the MGB technique by
Rutledge [1]. We used a long omega loop in order to achieve
marked effect on diabetes as well as weight-loss. All operations
were performed under general anesthesia using a standard 5-port
laparoscopy. After carbon dioxide insufflation, a 15-cm-long
gastric tube was divided along the lesser curvature starting at
the crow’s foot with Endo-GIA® (Medtronic, Minneapolis,
MN, USA) staplers and calibrated with a 40Fr bougie. A jejunal
loop was lifted 250–275 cm from the ligament of Treitz and
anastomosed antecolic to the gastric tube with an endo-GIA
stapler. The remaining anastomotic defect was sewn with a run-
ning 3–0 Vicryl (Ethicon, Somerville, New Jersey, USA) suture
intra-abdominally. Anastomosis was tested with methylene blue
and the Petersen defect was closed for all patients. No abdominal
drainage, urinary catheter, nor naso-gastric tubewere left in place
for any of the patients. All patients were mobilized and received
oral liquids within 2 h after the operation.
Hepatobiliary Scintigraphy
Mebrofenin labeled with 99mTechnethium (Bridatec, GE
Healthcare Life Sciences Core Imaging, Pittsburgh, PA,
USA) was used as bile tracer after a 12-h fasting period.
Intravenously injected mebrofenin is cleared by the liver and
conjugated to bile. Thus, bile flow through the intestine can be
observed by detecting the fate of the tracer [12]. Imaging
consisted of dynamic gamma camera (Symbia T2 System;
Siemens, Munich, Germany) imaging with a low-energy col-
limator, a static image, and single-photon emission computed
tomography/computed tomography (SPECT-CT). Dynamic
imaging (72 frames × 50 s) began from the 99mTc-mebrofenin
injection and continued for 60 min. Tracer injection
(190MBq) was given in supine position into cubital vein with
a gamma camera detector above the patients’ abdomen. A
10 min static image and SPECT-CTwas taken 2 h after tracer
injection in order to localize BR in the esophagus or the gastric
tube. SPECTwas performed by acquiring 60 projections (20 s
per projection) over 180° on a non-circular imaging mode.
A nuclear medicine physician first estimated the dynamic
data. If BR was detected, a region of interest (ROI) was placed
into that area. The onset of BR, its duration, and activity were
defined from the time activity curves. The amount of
duodenogastric bile reflux (BRi) was calculated as ratio of
total counts in the first frame of the dynamic series in the liver
to maximum activity in the ROI. Fatty meal stimulation for
gallbladder emptying was not used in this study.
Endoscopic and Histological Assessment
Four patients with a BR-positive scintigraphy were invited for
a gastroscopy with biopsies. Gastroscopies were performed
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without sedation with a flexible endoscope (Olympus Q190,
Tokyo, Japan) and mucosal biopsies were obtained from the
gastric tube, cardia, and esophagus. Biopsy specimen was
prepared with serial sections (5 μm thick) from formalin-
fixed and paraffin-embedded biopsy specimen after
hematoxylin-eosin (HE) and AB-PAS-staining.
Reflux Symptom Questionnaire (GerdQ)
GerdQ questionnaire was developed as a clinical tool for eval-
uation reflux symptoms [11].The original questionnaire is in
English, but the patients in our series are native speakers of
either Finnish or Swedish. We used a previously validated
Swedish version of the questionnaire and we translated the
questionnaire into Finnish according to a validated translation
procedure in which two native speakers of Finnish translated
the questionnaire from English to Finnish. A third native
speaker of Finnish created a reconciled version which was
translated back to English by a native speaker of Finnish and
English. The back translation was essentially identical to the
original version and therefore the interim version was accept-
ed for pilot testing with ten patients with gastrointestinal reflux
disease. After pilot testing, the final translation was approved
by consensus of all parties involved.
Results
Nine patients (five men) underwent MGB between December
2014 and April 2015. Mean age at operation was 56.2 years
(41–65). Mean preoperative BMI was 43.1 kg/m2 (34.2–
54.6). Mean %EWL was 25.4% (12.0–34.8), 51.5% (29.4–
72.8), and 70.1% (41.2–108.7) at 1, 3, and 6 months and
83.9% (49.5–128.3) at 12 months, respectively (Table 1).
Prior to surgery, seven patients had type 2 diabetes for
12.9 years (5.0–30.0) and four of them were insulin-depen-
dent. During the follow-up, four patients reached a complete
remission of diabetes and two patients became independent of
insulin. Resolution of high blood pressure and dyslipidemia
was observed in three and two patients, respectively (Table 2).
Table 1 Patient demographics and weight-loss during the follow-up
Gender Age (y) BMI (kg/m2) %EWL
Preop 12 mo 12 mo
Patient 1 F 51 37.3 26.7 88.2
Patient 2 M 64 45 33 76.3
Patient 3 M 51 50.9 38 49.5
Patient 4 M 55 40.7 26.2 92.3
Patient 5 M 65 35.3 27 78.0
Patient 6 F 56 52.8 29.6 73.6
Patient 7 M 41 34.6 22.7 128.3
Patient 8 F 64 37.8 23.9 109.0
Patient 9 F 59 48.4 34.29 60.3
y years, mo months, BMI body mass index, %EWL excess weight-loss,
preop prior to mini-gastric bypass
Table 2 Characterization of
obesity-related conditions DMII duration (y) Diabetes medication HbA1C (mmol/mol) Comorbidities









6 = sleep apnea
preop 12 mo preop 12 mo Preop 12 mo
Patient 1 5 1 0 37 29 1 4 6 0
Patient 2 7 1 0 41 31 1 2 4 6 0
Patient 3 0 0 0 40 36 2 3 4 6 2 3 4 6
Patient 4 14 2 1 53 30 1 3 4 1
Patient 5 30 2 2 48 47 1 2 3 4 6 1 3 4
Patient 6 0 0 0 38 32 4 6 4 6
Patient 7 14 2 0 59 34 1 2 3 4 6 2 3 4 6
Patient 8 12 2 1 81 44 1 2 3 1
Patient 9 8 1 0 45 35 1 2 3 4 5 6 2 4 6
DMII type 2 diabetes mellitus, y years, momonths, preop prior to mini-gastric bypass, HbA1C glycohemoglobin
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Hepatobiliary scintigraphywas performed for all patients at
10.7months (8.6–13.0) after the surgery. Five patients had BR
into the gastric tube during the scan (Fig. 1). Selected images
of one representative patient are shown in Fig. 2. Bile tracer
was found in the gastric tube as early as 23 min from the tracer
injection for one patient (range 23–58 min) and maximum
activity was observed at 58 min (Fig. 1). Highest concentra-
tion of bile tracer (BRi) in the gastric tube during the scan was
8% (1–8%) ofmaximal activity. Concentration of bile tracer in
the gastric tube was diminishing at the end of the 60-min scan,
but total resolution of bile tracer was not observed. There was
no sign of bile reflux into the esophagus in any of the SPECT/
CT scans.
GerdQ scores of two patients were above 8, which corre-
lates with reflux disease. One of them had BR into the gastric
tube in scintigraphy. Neither of them had BR into the
esophagus.
An additional gastroscopy was done for all patients with a
sign of BR in hepatobiliary scintigraphy. Four patients were
invited for a gastroscopy at 14.4 months (12.4–16.7). Three of
them had a normal endoscopic finding as well as normal his-
tology in biopsies. One patient had mild esophagitis in the
endoscopic assessment and similar finding in biopsies from
the Z-line. He had no reflux symptoms (GerdQ score 5), and
there was no evidence of BR into the esophagus in
Fig. 1 Time-activity curves for five study subjects with bile tracer
activity in the gastric tube during scintigraphy. Time from tracer
injection is on x-axis and recorded tracer activity (pulse intensity) in the
gastric tube on y-axis
Fig. 2 Dynamic scan of one
representative patient. Frame
number is x-y followed by time
from injection of bile tracer
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scintigraphy nor in the endoscopic assessment. Prior to sur-
gery, he had similar findings in gastroscopy. One patient had a
gastroscopy prior to scintigraphy at 10.1 months after the op-
eration due to malabsorption and reflux symptoms. He had
GerdQ score 12, which is considered significant for reflux
disease. His endoscopic assessment and biopsies showed gas-
tritis without HP infection but no esophagitis. Prior to MGB,
he had normal endoscopy findings with normal biopsies. A
24-h impedance and pH measurement of the esophagus and
gastric tube showed a continuous non-acid reflux. At
12 months, he had iron deficiency and hypoalbuminemia re-
quiring intravenous administration of iron as well as dietary
supplementation of protein. Due to difficult reflux symptoms
and malabsorption, he underwent revision surgery in which
MGB was converted to Roux-en-Y gastric bypass (RYGB)
with 60 cm biliary and 120 cm alimentary limbs.
One other patient without any sign of BR in the scintigra-
phy reported heartburn and reflux symptoms and had GerdQ
score 11. She was diagnosed with a marginal ulcer, which
healed with proton pump inhibitor. Another patient with a
negative scintigraphy reported difficulties in swallowing. He
was diagnosed with intestinal metaplasia at the gastroesopha-
geal junction in gastroscopy at 9 months after the surgery.
Prior to surgery, he had a similar macroscopic finding in gas-
troscopy but no biopsies were obtained. A 24-h esophageal
pH measurement revealed a difficult night-time acid reflux.
Conclusion
MGB technique was developed as a modification of the
Mason’s loop gastric bypass in which a transverse gastric
pouch was divided at the fundus. McCarthy et al. reported
endoscopic evidence of gastritis in 71% and high concentra-
tions of bile acids in the gastric pouch after Mason’s loop
procedure in 28 randomly selected patients after mason’s loop
gastric bypass in 1985 [13]. It has been stated the modification
of the gastric pouch has diminished the bilious contents in the
gastric tube and esophagus but the exposure of ventricular and
esophageal mucosa to bile and the clinical relevance of it are
not yet disclosed [14].
In a retrospective analysis of five centers, the main indica-
tion for revision surgery after MGB was BR [6]. Two large
studies with 1000 patients reported a re-operation rate of 0.4
and 0.7% due to BR after MGB. However, completeness of
follow-up was not reported in these studies [2, 14]. Data on
non-symptomatic BR after MGB has not been published.
High levels of BR have been found in non-obese patients with
Barrett’s esophagus in two previous studies [15, 16]. Bile
reflux gastritis has also been found to associate with intestinal
metaplasia at the cardia [17]. On the other hand, in another
study, the risk for Barrett’s esophagus was not significantly
related to higher concentrations of bile acids in the stomach
[18]. The role of bile acids as a risk factor for gastric carcino-
ma has been a subject of discussion, especially in conjunction
with H. pylori (HP) colonization [19]. In fact, BR has been
reported to cause more severe mucosal lesions in patients with
chronic gastritis, especially in conjunction with HP [20].
BR has been stated to cause acute and chronic inflammatory
changes in the gastric mucosa along with histological changes in
gastro-esophageal junction, which eventually may lead to
Barrett’s esophagus [21]. According to a systematic review by
McQuaid et al., bile acids have been found to induce esophageal
squamous cells to resemble intestinal-type cells and to promote
Barrett’s cells to increase intestinal type genes in in vitro studies
[22]. However, Nason et al. did not find similar results in vivo
[18]. Park et al. showed that bile acids induce COX-2 expression
in gastric cells to generate intestinal metaplasia and predispose to
neoplastic changes in the gastric mucosa [23].
BR in the stomach is also considered a physiologic phe-
nomenon. According to the Society of Nuclear Medicine
guidelines for hepatobiliary scintigraphy, activity may reflux
from the duodenum into the stomach but a marked BR in a
symptomatic patient correlates with bile gastritis [12].
Previous scintigraphic studies of healthy unoperated controls
by Tolin et al. and Mackie et al. have shown a BR into the
stomach with mean BRi 10 and 8%, respectively [24, 25].
Chen et al. compared hepatobiliary scintigraphies of patients
with a known duodenogastric reflux disease with healthy con-
trols. They found significantly higher amounts of bile tracer in
the ventricles of patients with a known duodenogastric reflux
disease with BRi up to 28%. Also in this study, all healthy
controls but one had evidence of BR with BRi 1–9% [9]. In
our series, the highest amount of bile tracer in the gastric tube
after MGB was 8%, which is similar to the finding of healthy
subjects in these previous scintigraphic studies.
Tolone et al. studied high resolution manometries after
omega-loop gastric bypass. They discovered that intragastric
pressures and gastroesophageal pressure gradient statistically
diminished after the surgery. They concluded that this would
result in a decreased incidence of gastroesophageal reflux after
omega-loop gastric bypass [26].
A review byMahawar et al. addressed the issue of BR after
MGB [27]. They concluded that according to the literature,
BR will lead to higher incidence of histological gastritis, but it
does not always translate into adverse symptomatic outcome.
Sundbom et al. studied hepatobiliary scintigraphies after
RYGB operations, and they found BR into the excluded stom-
ach in 36% of patients. The effect of bile might be more
harmful for the mucosa of the excluded stomach after
RYGB compared to the gastric pouch after MGB due to the
fact that bile in the excluded stomach will not be diluted or
mixed with normal gastric contents as liquid and solid food
are not passing through the excluded ventricle [28].
Risk of gastric cancer has been associated with gastric sur-
gery in previous studies. This has been thought to be a
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consequence of BR induced by gastric surgery [29, 30].
However, later, it has been stated that the increased gastric
cancer risk after gastric surgery is most likely because of syn-
ergistic effect of BR and HP infection [19]. Therefore, HP
eradication prior to gastric bypass surgery is of utmost impor-
tance. In a systematic review by Scozzari et al. in 2013, 33
cases of carcinoma after bariatric surgery were reported [31].
To date, only one case of gastric carcinoma afterMGB has been
published [32]. It is noteworthy that all cases of gastric carci-
noma after gastric bypass operations have been in the bypassed
stomach. The role of BR in the carcinogenesis in the bypassed
stomach is unclear and needs further investigation.
BR after MGB is a subject of ongoing debate, even though
until now there has not been a study that actually demonstrated
BR after MGB. Everyone agrees that bile exposure to esopha-
geal mucosa is extremely harmful. The effect of bile exposure
to the gastric mucosa on the other hand is more controversial.
Our case series demonstrates a modest BR in hepatobiliary
scintigraphy afterMGB in five out of nine consecutive patients.
However, none of the patients had any sign of bile reflux into
the esophagus. The amount of bile in the gastric tube was fairly
small but the entire duration of BR could not be determined by
this method. Only one patient with recorded BR had reflux
symptoms as well as histologic gastritis and he required re-
operation due to malabsorption and non ulcerative GERD.
Gastric biopsies of non-symptomatic patients with a positive
scintigraphy did not show foveolar hyperplasia or other inflam-
matory changes in the gastric tube. This is either due to the fact
that the amount of bile in the gastric tube is not enough to cause
histologic changes or it may also be due to a fairly short time
between surgery and follow-up gastroscopy. Two patients had
reflux symptoms with a negative BR finding in scintigraphy.
All things considered, scintigraphies did not correlate well with
clinical findings of bile reflux.
Our study is limited due to small number of participants
and lack of a control group. The imaging protocol was not
originally designed for the detection of bile reflux after bariat-
ric surgery and therefore it has some limitations: We used our
routine protocol that included an anterior 60 min dynamic
scan of the thorax and abdomen. It is possible that some tran-
sient late esophageal BR peaks were missed. Also, our proto-
col does not tell us whether BR is present beyond the 60 min
scan. An intermittent scan during a longer period of time
would provide more information.
This is the first report on hepatobiliary scintigraphies after
MGB. Our results indicate that transient bile reflux is common
after MGB in the gastric tube, but not in the esophagus. The
clinical relevance of bile reflux needs further studies.
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